Other pan-PI3K inhibitors, such as Pictilisib (GDC-0941) [179] and Pilaralisib (XL147) [146], have been studied in multiple clinical trials, including both HER2+ and HER2- breast cancer cohorts. This evidence concerns the gene ERBB2 and breast carcinoma.